Compare WSHP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSHP | EVO |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | British Virgin Islands | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | WSHP | EVO |
|---|---|---|
| Price | $87.02 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 12.9K | ★ 253.2K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,110,047.00 | ★ $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 428.16 | N/A |
| 52 Week Low | $20.02 | $2.84 |
| 52 Week High | $250.00 | $4.80 |
| Indicator | WSHP | EVO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 61.17 |
| Support Level | N/A | $3.10 |
| Resistance Level | N/A | $3.23 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 97.92 |
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the Company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.